For comments, suggestions
Created with Raphaël 2.1.0 01.11.2016 Filing date 04.06.2018 Validation fee payment 31.10.2018 (A1) Patent application published 19.03.2021 AGEPI application filing date 31.05.2021 (T2) Translation of the validated European patent 25.04.2025 01.11.2025 Valid until 02.11.2026 Renewal fee to be paid until 01.11.2036 Patent will expire on

Patent in force


(210)Number of the EPO application16862791
(220)Filing date of the EPO application2016.11.01
(80)EPO patent specification publication (B)EPB nr. 03/2021, 2021.01.20
(110)EPO patent number3370770
(11)Number of the documentMD 3370770 T2
(21)Number of the applicatione 2018 0897
(71)Name(s) of applicant(s), code of the countryJANSSEN BIOTECH INC., US;
(72)Name(s) of inventor(s), code of the countryJANSSON Richard, US;
KUMAR Vineet, US;
(73)Name(s) of owner(s), code of the countryJANSSEN BIOTECH INC., US;
(54)Title of the inventionSubcutaneous formulations of anti-cd38 antibodies and their uses
(13)Kind-of-document code T2
(51)International Patent Classification A61K 39/395 (2006.01.01); A61K 31/4439 (2006.01.01); A61K 31/198 (2006.01.01); A61K 31/573 (2006.01.01); A61K 31/69 (2006.01.01); C07K 16/28 (2006.01.01); A61K 9/10 (2006.01.01); A61K 47/12 (2006.01.01); A61K 47/20 (2006.01.01); A61K 47/22 (2006.01.01); A61P 35/00 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2018.10.31
(49)Date of publication of the translation of the validated European patent specification2021.05.31
(30)Priority201562250016 P, 2015.11.03, US
(74)Patent attorney(Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova
(86)International applicationPCT/US2016/059893, 2016.11.01
(87)International publicationWO 2017/079150, 2017.05.11
Up
/Inventions/details/3370770